Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the H.C. Wainwright Annual Global Life Sciences Conference.
| BRIDGEWATER, NJ,, May 17, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the H.C. Wainwright Annual Global Life Sciences Conference. The fireside chat will become available for on-demand viewing on May 24, 2022 at 7:00 a.m. ET and can be accessed by visiting the investor relations section of the Company’s website at www.insmed.com. The webcast will be archived for a period of 30 days following the presentation date. About Insmed Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com. Contact: Investors: Eleanor Barisser Media: Mandy Fahey
SOURCE Insmed Incorporated | ||
Company Codes: NASDAQ-NMS:INSM |
View original content to download multimedia:
